Epidemiology


Etiology

  • Idiopathic inflammatory autoimmune disorder of unknown etiology
  • Risk factors include:
    • Genetic disposition: associated with HLA-DR4 and HLA-DR1
    • Environmental factors (e.g., smoking)
    • Hormonal factors (premenopausal women are at the highest risk, suggesting a predisposing role of female sex hormones)

Pathophysiology

  • Certain interstitial tissue proteins (e.g. intracellular filament protein vimentin, filaggrin, type II collagen) undergo a posttranslational modification that involves the conversion of arginine to citrulline (citrullination).
  • Citrullinated proteins are recognized as foreign by the antigen-presenting cells that present them to CD4+ T cells.
  • Activation of CD4+ T cells leads to the following sequences of events:
    • IL-4 production → B-cell proliferation and differentiation → production of anticitrullinated peptide antibodies → type II hypersensitivity reaction and type III hypersensitivity reaction
    • Migration of CD4+ T cells to synovial joints → secretion of cytokines (IFN-γ, IL-17) → recruitment of macrophages → secretion of cytokines (TNF-α, IL-1, IL-6) → inflammation and proliferation
  • Bouts of inflammation, angiogenesis, and proliferation → proliferative granulation tissue with mononuclear inflammatory cells → pannus and synovial hypertrophy → invasion, progressive destruction, and deterioration of cartilage and bone
  • Antibodies against Fc portion of IgG (rheumatoid factor, RF) are produced to aid in removing autoantibodies and immune complexes.
    • RF excess triggers formation of new immune complexes and type III HSR
    • Individuals with positive RF are more likely to develop extraarticular manifestations.
  • Pasted image 20231014090158.png

Clinical features

Pasted image 20240221152545.png

Extraarticular manifestations

  • Rheumatoid nodules
    • Skin
      • Nontender, firm, subcutaneous swellings (2 mm–5 cm)
      • Commonly occur in areas exposed to higher pressure, e.g., extensor side of the forearm, bony prominencesPasted image 20240227143305.png
    • Lungs
      • Typically bilateral and peripheral
      • Rheumatoid pulmonary nodules may be accompanied by fibrosis and pneumoconiosis (Caplan syndrome).

Subtypes and variants


Atlantoaxial subluxation (Vertebral subluxation)

  • Definition: a potentially life-threatening complication caused by the inflammatory destruction of the ligaments affecting the atlantoaxial joint and the intervertebral joints
  • Clinical features
    • Pain and stiffness of the neck (typically early-morning neck pain at rest)
    • Head tilt
    • Neurological deficits
      • Cervical radiculopathy with peripheral paresthesias of the upper limb
      • In some cases, symptoms of high spinal cord compression
        • Slowly progressive spastic quadriparesis
        • Hyperreflexia or positive Babinski reflex
        • Respiratory insufficiency
  • Diagnostics
    • Extension and flexion x-rays of the cervical spine
    • MRI

Warning

Endotracheal intubation can acutely worsen the subluxation and cause compression of the spinal cord and/or vertebral arteries.

Diagnostics


Pasted image 20240116151535.png

  • Anticitrullinated peptide antibodies (ACPA), e.g., anticyclic citrullinated peptide (anti-CCP)
    • Tissue inflammation causes arginine residues in proteins such as vimentin to be enzymatically converted into citrulline through a process called citrullination. This alters the shape of the proteins, which can then serve as neoantigens that generate an immune response.
  • Rheumatoid factor (RF): IgM autoantibodies against the Fc region of IgG antibodies

Differential diagnostics


Treatment

Acute anti-inflammatory treatment

  • Glucocorticoids
    • Systemic prednisone
      • Longer-term therapy: Only use in patients with highly active RA
  • NSAIDs and selective COX-2 inhibitors: relieve symptoms, but do not improve the prognosis

Long-term pharmacological treatment

Disease-modifying antirheumatic drugs (DMARDs)

  • Methotrexate (MTX): first-line treatment in patients with moderate to high disease activity
    • To minimize adverse effects, administer folic acid.

Biologic DMARDs

  • Indication: persistent moderate or severe disease activity after 3 months of conventional DMARD therapy
  • Agents
    • TNF-α inhibitors: e.g., adalimumab, infliximab, etanercept
      • a receptor molecule (cept)

Complications